GI
ACAD icon

GAMMA Investing’s Acadia Pharmaceuticals ACAD Stock Holding History

GAMMA Investing’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$81.9K Buy
4,064
+1,079
+36% +$29K ﹤0.01% 2024
2026
Q2 		$75.5K Buy
2,985
+402
+16% +$8.85K ﹤0.01% 2018
2026
Q1 		$57.5K Sell
2,583
-826
-24% -$19.7K ﹤0.01% 2098
2025
Q4 		$91.1K Buy
3,409
+48
+1% +$1.15K ﹤0.01% 1646
2025
Q3 		$71.7K Buy
3,361
+690
+26% +$16.3K ﹤0.01% 1751
2025
Q2 		$57.6K Sell
2,671
-842
-24% -$15.7K ﹤0.01% 1837
2025
Q1 		$58.4K Buy
3,513
+3,030
+627% +$55K ﹤0.01% 1688
2024
Q4 		$8.86K Buy
483
+196
+68% +$3.16K ﹤0.01% 2675
2024
Q3 		$4.41K Buy
287
+119
+71% +$1.99K ﹤0.01% 2794
2024
Q2 		$2.73K Sell
168
-195
-54% -$3.15K ﹤0.01% 2791
2024
Q1 		$6.71K Sell
363
-21
-5% -$520 ﹤0.01% 2265
2023
Q4 		$9.95K Buy
+384
New +$9.17K ﹤0.01% 1906

Other funds holding ACAD

GI
Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

GAMMA Investing's ACAD Position: Q3 2026 in Review

GAMMA Investing increased its Acadia Pharmaceuticals (ACAD) stake by 36% in Q3 2026, buying an estimated $29K and bringing the position to 4,064 shares worth $81.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2024.

GAMMA Investing first reported a position in ACAD in Q4 2023 and has held it in 12 quarters since. The position peaked at $91.1K in Q4 2025. 10 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • GAMMA Investing held 4,064 shares of Acadia Pharmaceuticals worth $81.9K as of Q3 2026.
  • GAMMA Investing bought 1,079 Acadia Pharmaceuticals shares in Q3 2026, an estimated $29K.
  • Acadia Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2024 holding.
  • GAMMA Investing first reported a position in Acadia Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Acadia Pharmaceuticals position peaked at $91.1K in Q4 2025.
  • 10 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.